S15 Ep43: Medical Crossfire®: The Who, When, and How of TROP2-Targeting ADCs, ICIs, and PARP Inhibition in Triple-Negative Breast Cancer
OncLive® On Air
00:00
Immune therapy: KEYNOTE‑355 results
Heather McArthur reviews KEYNOTE‑355 showing PFS and a seven‑month OS improvement with pembrolizumab in PD‑L1 CPS≥10 disease.
Play episode from 04:04
Transcript
